Drug Trial Radar · NCT07518186
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
May 31, 2026
Primary completion
Apr 29, 2029
Study completion Dec 8, 2032
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Conditions
- Multiple Myeloma
Interventions
JNJ-79635322Drug
JNJ-79635322 will be administered as SC injection.
TeclistamabDrug
Teclistamab will be administered as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response (CR) or BetterTime frame: Up to approximately 41 months
- Progression-Free Survival (PFS)Time frame: Up to approximately 41 months
Locations
173 sites in 18 countries. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama · Recruiting
Mayo Clinic 1
Phoenix, Arizona · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Beverly Hills Cancer Center Clinical Research Advisors LLC
Beverly Hills, California · Recruiting
UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
University of California Irvine Medical Center
Orange, California · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
University of Connecticut Health Center
Farmington, Connecticut · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Memorial Cancer Institute
Pembroke Pines, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Rush University System for Health
Chicago, Illinois · Recruiting
Franciscan Health
Indianapolis, Indiana · Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
Mission Cancer Blood University of Iowa Health Care
Waukee, Iowa · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
LSU Health Feist Weiller Cancer Center
Shreveport, Louisiana · Recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
Tufts Medical Center
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
University Of Minnesota Medical Center
Minneapolis, Minnesota · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Astera Cancer Care
East Brunswick, New Jersey · Recruiting
Christus St. Vincent Regional Cancer Center
Santa Fe, New Mexico · Recruiting
New York Oncology Hematology
Albany, New York · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
NYU Langone Health Manhattan
New York, New York · Recruiting
New York Cancer and Blood Specialists
Shirley, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Gabrail Cancer Center
Canton, Ohio · Recruiting
The Christ Hospital
Cincinnati, Ohio · Recruiting
Dayton Physicians Network Urology
Dayton, Ohio · Recruiting
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon · Recruiting
Bon Secours Saint Francis Cancer Center
Greenville, South Carolina · Recruiting
Tennessee Oncology, PLLC
Nashville, Tennessee · Recruiting
Baylor University Medical Center
Dallas, Texas · Recruiting
Joe Arrington Cancer Research Treatment Center
Lubbock, Texas · Recruiting
Utah Cancer Specialists
Salt Lake City, Utah · Recruiting
Showing 40 of 173 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.